Kangmei Pharmaceutical (600518.SH): currently not involved in AI medicine.

Kangmei Pharmaceutical (600518.SH) stated on the interactive platform on November 22 that the business of the company does not currently involve AI medicine.

Gelonghui FinanceNov 22 17:09

Kangmei Pharmaceutical (600518.SH): Currently, there are no plans for restructuring.

On November 22, 2023, Gelonghui reported that Kangmei Pharmaceutical (600518.SH) stated on its interactive platform that the company currently has no plans for reorganization. The company will strictly abide by relevant regulations and fulfill its information disclosure obligations in a timely manner. Relevant information should refer to the announcements disclosed by the company. The company will continue to advance the implementation of the "12355" global strategy, positioning itself as a smart medical health brand enterprise centered on traditional Chinese medicine pieces, tightly focusing on the two main strategic lines of "creating a complete value chain for traditional Chinese medicine pieces" and "providing specialized services for medical rehabilitation and health care," with five major areas: traditional Chinese medicine, medical rehabilitation, traditional Chinese medicine city, health products, and pharmaceutical commerce.

Gelonghui FinanceNov 22 17:00

Express News | Yesterday, 31 stocks had a net buy financing of over 0.1 billion yuan, with chongqing sokon industry group stock net buying 0.64 billion yuan.

BreakingsNov 14 09:16

Kangmei Pharmaceutical (600518.SH) has seen no major changes in its fundamentals, and its profitability still needs further recovery.

Gelonghui November 11th | Kangmei Pharmaceutical (600518.SH) announced that on November 11, 2024, the company's stocks continued to hit the limit up, with a significant short-term increase in stock prices. In the first three quarters of 2024, the company achieved revenue of 3873.5583 million yuan, with a net income attributable to shareholders of the listed company of 5.0155 million yuan, and a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of -179.5222 million yuan. The company's production operation is currently normal, and the fundamentals have not undergone significant changes, with profitability still needing further recovery. The board of directors of the company confirmed, in addition to what has been publicly disclosed.

Gelonghui FinanceNov 11 16:34

Express News | Kangmei Pharmaceutical: The company's stock price has experienced a significant short-term increase. Investors are advised to pay attention to the risks.

BreakingsNov 11 16:29

Express News | The largest increase in margin trading balance this week: HoLuc Bo margin trading balance: 0.22 billion yuan, with a balance growth rate of 949.58%; Kangmei Pharmaceutical margin trading balance: 0.732 billion yuan, with a balance growth rate of 166.12%.

BreakingsNov 10 20:20